US2018214421A1PendingUtilityA1

Compositions, methods and kits for reducing lipid levels

Assignee: NUSIRT SCIENCES INCPriority: Mar 15, 2013Filed: Dec 21, 2017Published: Aug 2, 2018
Est. expiryMar 15, 2033(~6.7 yrs left)· nominal 20-yr term from priority
A61P 3/10A61P 9/10A61P 43/00A61P 3/06A61P 3/04A61K 31/706A61K 31/435A23L 33/175A23L 33/15A23V 2002/00A61K 45/06A61K 31/455A61K 31/198A61K 31/05A61K 2300/00A23V 2250/0628A23V 2250/7046A23V 2200/3262A61K 47/183
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions, methods, and kits useful for treating hyperlipidemic conditions are provided herein. Such compositions can contain synergizing amounts of nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites in combination with leucine and/or a leucine metabolite, with or without resveratrol.

Claims

exact text as granted — not AI-modified
1 - 103 . (canceled) 
     
     
         104 . A composition comprising:
 a. at least about 250 mg of leucine and/or at least about 25 mg of one or more leucine metabolites, wherein the one or more leucine metabolites are selected from the group consisting of keto-isocaproic acid (KIC), alpha-hydroxy-isocaproic acid, and HMB; and   b. at least about 1 mg of nicotinic acid and/or nicotinamide riboside and/or one or more nicotinic acid metabolites, wherein the nicotinic acid metabolite is selected from the group consisting of nicotinyl CoA, nicotinuric acid, nicotinate mononucleotide, nicotinate adenine dinucleotide, and nicotinamide adenine dinucleotide.   
     
     
         105 . The composition of  claim 104 , wherein the composition is substantially free of nicotinamide. 
     
     
         106 . The composition of  claim 104 , wherein the component (a) in the composition in leucine and the component (b) in the composition is nicotinic acid. 
     
     
         107 . The composition of  claim 104 , wherein the amount of leucine and/or one or more leucine metabolites is less than about 1300 mg. 
     
     
         108 . The composition of  claim 104 , wherein the amount of nicotinic acid and/or nicotinamide riboside and/or one or more nicotinic acid metabolites is less than about 250 mg. 
     
     
         109 . The composition of  claim 104 , wherein the amount of nicotinic acid and/or nicotinamide riboside and/or one or more nicotinic acid metabolites is between about 1-100 mg. 
     
     
         110 . The composition of  claim 104 , wherein the composition further comprises resveratrol. 
     
     
         111 . The composition of  claim 104 , wherein the composition is a tablet, a capsule, or a pill. 
     
     
         112 . The composition of  claim 104 , wherein the composition is substantially free of valine and isoleucine. 
     
     
         113 . The composition of  claim 104 , wherein the composition contains less than about  10 % of non-leucine amino acids. 
     
     
         114 . The composition of  claim 104 , further comprising one or more therapeutic agents is selected from the group consisting of HMG-CoA inhibitor, fibrate, bile acid sequestrant, ezetimibe, lomitapide, phytosterols, CETP antagonist, orlistat, and any combination thereof. 
     
     
         115 . The composition of  claim 104 , wherein the composition is formulated in a unit dosage form. 
     
     
         116 . A method of lowering total cholesterol level or total lipid content in a subject in need thereof, comprising administering to said subject the composition of  claim 104  to effect a reduction in the total cholesterol level in the subject or total lipid content. 
     
     
         117 . A composition comprising:
 a. at least about 250 mg of leucine and/or 25 mg of one or more leucine metabolites, wherein the one or more leucine metabolites are selected from the group consisting of keto-isocaproic acid (KIC), alpha-hydroxy-isocaproic acid, and HMB; and   b. at least about 1 mg of nicotinic acid and/or nicotinamide riboside and/or one or more nicotinic acid metabolites, wherein the nicotinic acid metabolite is selected from the group consisting of nicotinyl CoA, nicotinuric acid, nicotinate mononucleotide, nicotinate adenine dinucleotide, and nicotinamide adenine dinucleotide, and   
       wherein the molar ratio of component (a) to (b) in said composition is greater than about 5. 
     
     
         118 . The composition of  claim 117 , wherein the molar ratio of component (a) to (b) is less than about 100. 
     
     
         119 . The composition of  claims 117 , wherein the composition is substantially free of nicotinamide. 
     
     
         120 . The composition of  claims 117 , wherein the component (a) in the composition is leucine and the component (b) in the composition is nicotinic acid. 
     
     
         121 . The composition of  claims 117 , wherein the amount of leucine and/or one or more leucine metabolites is less than about 1300 mg. 
     
     
         122 . The composition of  claims 117 , wherein the amount of nicotinic acid and/or nicotinamide riboside and/or one or more nicotinic acid metabolites is between about 1-100 mg. 
     
     
         123 . The composition of  claims 117 , wherein a portion of the leucine and/or one or more leucine metabolites is in a free form. 
     
     
         124 . The composition of  claims 117 , wherein the composition is a tablet, a capsule, or a pill. 
     
     
         125 . The composition of  claims 117 , wherein the composition is formulated in a unit dosage form. 
     
     
         126 . A method of lowering total cholesterol level or total lipid content in a subject in need thereof, comprising administering to said subject the composition of  claims 117  to effect a reduction in the total cholesterol level or total lipid content in the subject.

Join the waitlist — get patent alerts

Track US2018214421A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.